Wells Fargo Maintains an 'Outperform' on Salix Pharmaceuticals (SLXP); Buy on Weakness

Wells Fargo maintains an 'Outperform' on Salix Pharmaceuticals (NASDAQ: SLXP).

Analyst, Michael Tong, thinks today's weakness on in response to approval of generic versions of Viropharma's (Nasdaq: VPHM)(Not Rated) Vancocin.

Tong said, "We believe the association is due to the fact that Vancocin and SLXP's Xifaxan are both considered orallyadministered and locallyacting antibiotics. As such, FDA's denial of VPHM's Citizen Petition could foreshadow nearterm approval of generic Xifaxan...In our view, this connection is misplaced."

For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.

Shares of Salix Pharmaceuticals closed at $50.01 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AMD (AMD) to offer senior notes in four parts
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald